Fiona Yull

Last active: 3/21/2018

  1. Targeting the Wnt pathway in synovial sarcoma models. Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, VanSaun MN, Fingleton B, Gleaves L, Orton D, Capecchi MR, Blackwell TS, Lee E, Yull F, Eid JE (2013) Cancer Discov 3(11): 1286-301
    › Primary publication · 23921231 (PubMed) · PMC3823757 (PubMed Central)
  2. Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, Moore MM, Lwin ST, Yull FE, Mundy GR, Elefteriou F (2013) J Bone Miner Res 28(4): 960-9
    › Primary publication · 23172686 (PubMed)
  3. NF-κB inhibition after cecal ligation and puncture reduces sepsis-associated lung injury without altering bacterial host defense. Li H, Han W, Polosukhin V, Yull FE, Segal BH, Xie CM, Blackwell TS (2013) Mediators Inflamm : 503213
    › Primary publication · 24347827 (PubMed) · PMC3852536 (PubMed Central)
  4. NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-κB activity. Han W, Li H, Cai J, Gleaves LA, Polosukhin VV, Segal BH, Yull FE, Blackwell TS (2013) J Immunol 190(9): 4786-94
    › Primary publication · 23530143 (PubMed) · PMC3633681 (PubMed Central)
  5. Mother-daughter communication about breast cancer risk: interpersonal and biological stress processes. Berlin KL, Andreotti C, Yull F, Grau AM, Compas BE (2013) J Behav Med 36(3): 328-39
    › Primary publication · 22569774 (PubMed)
  6. Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, Smith CA, Yull FE, Duvall CL, Giorgio TD (2013) Mol Pharm 10(3): 975-87
    › Primary publication · 23331322 (PubMed) · PMC3595119 (PubMed Central)
  7. Tumor microenvironment complexity: emerging roles in cancer therapy. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA (2012) Cancer Res 72(10): 2473-80
    › Primary publication · 22414581 (PubMed) · PMC3653596 (PubMed Central)
  8. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Arima Y, Harada M, Kamimura D, Park JH, Kawano F, Yull FE, Kawamoto T, Iwakura Y, Betz UA, Márquez G, Blackwell TS, Ohira Y, Hirano T, Murakami M (2012) Cell 148(3): 447-57
    › Primary publication · 22304915 (PubMed)
  9. Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis. Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, Vassiliou S, McMahon F, Gleaves LA, Han W, Stathopoulos I, Zakynthinos SG, Yull FE, Roussos C, Kalomenidis I, Blackwell TS, Stathopoulos GT (2012) Carcinogenesis 33(4): 859-67
    › Primary publication · 22287559 (PubMed) · PMC3324442 (PubMed Central)
  10. Intraductal injection of LPS as a mouse model of mastitis: signaling visualized via an NF-κB reporter transgenic. Barham W, Sherrill T, Connelly L, Blackwell TS, Yull FE (2012) J Vis Exp (67): e4030
    › Primary publication · 22971993 (PubMed) · PMC3490260 (PubMed Central)